CA2368967A1 - Telomerase-specific cancer vaccine - Google Patents
Telomerase-specific cancer vaccine Download PDFInfo
- Publication number
- CA2368967A1 CA2368967A1 CA002368967A CA2368967A CA2368967A1 CA 2368967 A1 CA2368967 A1 CA 2368967A1 CA 002368967 A CA002368967 A CA 002368967A CA 2368967 A CA2368967 A CA 2368967A CA 2368967 A1 CA2368967 A1 CA 2368967A1
- Authority
- CA
- Canada
- Prior art keywords
- telomerase
- peptide
- antigen
- amino acids
- length
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010017842 Telomerase Proteins 0.000 title claims abstract description 118
- 229940022399 cancer vaccine Drugs 0.000 title description 3
- 238000009566 cancer vaccine Methods 0.000 title description 2
- 108091007433 antigens Proteins 0.000 claims abstract description 117
- 102000036639 antigens Human genes 0.000 claims abstract description 116
- 239000000427 antigen Substances 0.000 claims abstract description 115
- 238000000034 method Methods 0.000 claims abstract description 57
- 229960005486 vaccine Drugs 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 19
- 201000011510 cancer Diseases 0.000 claims abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 72
- 239000002502 liposome Substances 0.000 claims description 44
- 150000001413 amino acids Chemical class 0.000 claims description 34
- 230000027455 binding Effects 0.000 claims description 22
- 150000002632 lipids Chemical class 0.000 claims description 22
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 19
- 108010002350 Interleukin-2 Proteins 0.000 claims description 15
- 102000000588 Interleukin-2 Human genes 0.000 claims description 15
- 238000006467 substitution reaction Methods 0.000 claims description 15
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 108010044720 telomerase reverse transcriptase (540-548) Proteins 0.000 claims description 7
- 210000000265 leukocyte Anatomy 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 31
- 230000005867 T cell response Effects 0.000 abstract description 12
- 238000009472 formulation Methods 0.000 abstract description 9
- 238000001727 in vivo Methods 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 46
- 102000004196 processed proteins & peptides Human genes 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 19
- 239000012634 fragment Substances 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 9
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000004044 response Effects 0.000 description 8
- -1 CD45R0 Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 238000013459 approach Methods 0.000 description 6
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000003411 telomere Anatomy 0.000 description 6
- 102000055501 telomere Human genes 0.000 description 6
- 108091035539 telomere Proteins 0.000 description 6
- 239000002691 unilamellar liposome Substances 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 4
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 4
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 4
- 210000003071 memory t lymphocyte Anatomy 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 3
- 101000868880 Homo sapiens Serpin B13 Proteins 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 102100032322 Serpin B13 Human genes 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 235000013930 proline Nutrition 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 235000004400 serine Nutrition 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 235000008521 threonine Nutrition 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 235000002374 tyrosine Nutrition 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 239000013616 RNA primer Substances 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 108700014844 flt3 ligand Proteins 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 210000004296 naive t lymphocyte Anatomy 0.000 description 2
- 229940022007 naked DNA vaccine Drugs 0.000 description 2
- 229940023146 nucleic acid vaccine Drugs 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
- 229930182819 D-leucine Natural products 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
- 108010086377 HLA-A3 Antigen Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 241001602876 Nata Species 0.000 description 1
- 101150075130 PNOC gene Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- XMQFTWRPUQYINF-UHFFFAOYSA-N bensulfuron-methyl Chemical class COC(=O)C1=CC=CC=C1CS(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 XMQFTWRPUQYINF-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000009172 cell transfer therapy Methods 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000010809 targeting technique Methods 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464457—Telomerase or [telomerase reverse transcriptase [TERT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Abstract
Telomerase-specific T-cell antigens are provided, which are useful in generating T-cell responses against telomerase. Formulations of telomerase antigens as vaccines are useful in treating and preventing cancer, using in vivo or ex vivo techniques.
Description
TELOMERASE-SPECIFIC CANCER VACCINE
BACKGROUND OF THE INVENTION
Telomeres, the DNA at the chromosome ends, are made up of simple tandem repeats. In most somatic cells, telomere sequences are lost during DNA
replication due to the need of DNA-dependent DNA polymerases for an RNA primer annealed to the template strand. Because the RNA primer cannot anneal beyond the 5' end of the DNA
strand, each time a cell's DNA replicates, short bits of telomeric DNA are lost with each generation. Cells displaying such telomeric shortening go into senescence after a fixed number of population doublings, and senescence correlates directly with the erosion of telomeres to a critical minimum length.
Not all cells undergo such loss. however. While normal human somatic cells lose telomeric repeats with each cycle of cell division, human germline and, significantly, cancer cells maintain a constant number of telomeric repeats. Telomere length is maintained in these cells by the action of telomerase, a ribonucleoprotein enzyme that uses a short endogenous RNA as a template for telomere addition. In fact, cancer cells express high levels of telomerase, whereas somatic cells express little, if any.
Because normal somatic cells do not appear to express or require telomerase, whereas cancer cells express high levels of telomerase, the telomerase enzyme presents an attractive therapeutic target. Due to the fact that telomerase is a normal "self' antigen, however, conventional vaccination strategies are unavailable. Thus, the focus of telomerase-based therapeutics has been enzyme inhibitors of various sorts, rather than vaccine-based approaches.
A need exists, therefore, for new telomerase-based therapeutic approaches.
This need extends to vaccines, based on telomerase antigens.
SUMMARY OF THE INVENTION
It is, therefore, an object of the invention to provide antigens that are useful in generating an immune response against telomerase. According to this object of the invention, telomerase antigens are provided that are capable of marshalling the immune system against telomerase-expressing cells. In one embodiment, telomerase antigens are provided, which are based on peptide sequences of the protein portion of telomerase. In another embodiment, telomerase antigens are provided as nucleic acids that are capable of being used to express peptide-based telomerase antigens.
It is another object of the invention to provide vaccine compositions which include at least one telomerase antigen. Thus, in one aspect, the invention provides vaccine compositions containing telomerase peptide antigens. In another aspect, polynucleotides are provided, which encode protein-based telomerase antigens.
It is still another object of the invention to provide methods of treating or preventing cancer. According to this object, the telomerase antigens of the invention may be directly administered in beneficial amounts to a patient. Also according to this object, the present telomerase antigens may be administered to a patient encoded in a nucleic acid. This object is also met by ex vivo methods that im~olve contacting a cell with a telomerase antigen, and administering that cell to a patient. In one aspect, the contacted cell may be an antigen presenting cell, which may be used to generate a primed T-cell ex vivo, at which time the primed T-cell may be administered to a patient.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows fluorescence activated cell sorting (FACS) analysis of T-cells activated by telomerase-specific antigens. Panels A and B are negative and positive controls, respectively, and panels C, D and E are antigen candidates.
BACKGROUND OF THE INVENTION
Telomeres, the DNA at the chromosome ends, are made up of simple tandem repeats. In most somatic cells, telomere sequences are lost during DNA
replication due to the need of DNA-dependent DNA polymerases for an RNA primer annealed to the template strand. Because the RNA primer cannot anneal beyond the 5' end of the DNA
strand, each time a cell's DNA replicates, short bits of telomeric DNA are lost with each generation. Cells displaying such telomeric shortening go into senescence after a fixed number of population doublings, and senescence correlates directly with the erosion of telomeres to a critical minimum length.
Not all cells undergo such loss. however. While normal human somatic cells lose telomeric repeats with each cycle of cell division, human germline and, significantly, cancer cells maintain a constant number of telomeric repeats. Telomere length is maintained in these cells by the action of telomerase, a ribonucleoprotein enzyme that uses a short endogenous RNA as a template for telomere addition. In fact, cancer cells express high levels of telomerase, whereas somatic cells express little, if any.
Because normal somatic cells do not appear to express or require telomerase, whereas cancer cells express high levels of telomerase, the telomerase enzyme presents an attractive therapeutic target. Due to the fact that telomerase is a normal "self' antigen, however, conventional vaccination strategies are unavailable. Thus, the focus of telomerase-based therapeutics has been enzyme inhibitors of various sorts, rather than vaccine-based approaches.
A need exists, therefore, for new telomerase-based therapeutic approaches.
This need extends to vaccines, based on telomerase antigens.
SUMMARY OF THE INVENTION
It is, therefore, an object of the invention to provide antigens that are useful in generating an immune response against telomerase. According to this object of the invention, telomerase antigens are provided that are capable of marshalling the immune system against telomerase-expressing cells. In one embodiment, telomerase antigens are provided, which are based on peptide sequences of the protein portion of telomerase. In another embodiment, telomerase antigens are provided as nucleic acids that are capable of being used to express peptide-based telomerase antigens.
It is another object of the invention to provide vaccine compositions which include at least one telomerase antigen. Thus, in one aspect, the invention provides vaccine compositions containing telomerase peptide antigens. In another aspect, polynucleotides are provided, which encode protein-based telomerase antigens.
It is still another object of the invention to provide methods of treating or preventing cancer. According to this object, the telomerase antigens of the invention may be directly administered in beneficial amounts to a patient. Also according to this object, the present telomerase antigens may be administered to a patient encoded in a nucleic acid. This object is also met by ex vivo methods that im~olve contacting a cell with a telomerase antigen, and administering that cell to a patient. In one aspect, the contacted cell may be an antigen presenting cell, which may be used to generate a primed T-cell ex vivo, at which time the primed T-cell may be administered to a patient.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows fluorescence activated cell sorting (FACS) analysis of T-cells activated by telomerase-specific antigens. Panels A and B are negative and positive controls, respectively, and panels C, D and E are antigen candidates.
2 DETAILED DESCRIPTION
The present invention relates to a telomerase-specific vaccines, which are useful generating telomerase-directed activated T-cells. More particularly the inventive vaccines are useful in generating antigen-specific major histocompatability-(MHC-) restricted T-cell responses against telomerase presented by antigen presenting cells. It is believed that the present vaccines act to relieve the tolerance or anergy induced through self tolerance mechanisms to telomerase in normal individuals. Since telomerase represents a cancer-specific therapeutic target, in one embodiment, the vaccines of the invention are useful in the treatment or prevention of a variety of cancers.
A. Definitions As used in this specification. an "activated T-cell" is one that is in the following phases of the cell cycle: the G, phase, the S phase, the G, phase or the M (mitosis) phase. Thus, an "activated T-cell" is undergoing mitosis and/or cell division.
An activated T-cell may be a T helper (TH) cell or a cytotoxic T-cell (cytotoxic T lymphocyte (CTL or T~)).
Activation of a naive T-cell may be initiated by exposure of such a cell to an antigen-presenting cell (APC) (which contains anti~en%MHC complexes) and to a molecule such as IL-1, IL-2, IL-12, IL-13, y-IFN, and similar lsmphokines. The antigen/MHC
complex interacts with a receptor on the surface of the T-cell (T-cell receptor (TCR)). Golub et al., eds. IMMUNOLOGY: A SYNTHESIS, Chapter ~: "The T-cell Receptor" (1991).
As used in this specification. "priming" is used to mean exposing an animal (including a human) or cultured cells to antigen, in a manner that results in activation and/or memory. The generation of CD4' and CDS- T-cell responses against a target antigen is usually dependent upon in vivo priming, either through natural infection or through deliberate immunization.
As used in this specification. a "naive" T-cell is one that has not been exposed to foreign antigen (non-autologous) antigen or one that has not been exposed to cryptic autologous antigen. A "naive" T-cell is sometimes referred to as an "unprimed"
T-cell. The
The present invention relates to a telomerase-specific vaccines, which are useful generating telomerase-directed activated T-cells. More particularly the inventive vaccines are useful in generating antigen-specific major histocompatability-(MHC-) restricted T-cell responses against telomerase presented by antigen presenting cells. It is believed that the present vaccines act to relieve the tolerance or anergy induced through self tolerance mechanisms to telomerase in normal individuals. Since telomerase represents a cancer-specific therapeutic target, in one embodiment, the vaccines of the invention are useful in the treatment or prevention of a variety of cancers.
A. Definitions As used in this specification. an "activated T-cell" is one that is in the following phases of the cell cycle: the G, phase, the S phase, the G, phase or the M (mitosis) phase. Thus, an "activated T-cell" is undergoing mitosis and/or cell division.
An activated T-cell may be a T helper (TH) cell or a cytotoxic T-cell (cytotoxic T lymphocyte (CTL or T~)).
Activation of a naive T-cell may be initiated by exposure of such a cell to an antigen-presenting cell (APC) (which contains anti~en%MHC complexes) and to a molecule such as IL-1, IL-2, IL-12, IL-13, y-IFN, and similar lsmphokines. The antigen/MHC
complex interacts with a receptor on the surface of the T-cell (T-cell receptor (TCR)). Golub et al., eds. IMMUNOLOGY: A SYNTHESIS, Chapter ~: "The T-cell Receptor" (1991).
As used in this specification. "priming" is used to mean exposing an animal (including a human) or cultured cells to antigen, in a manner that results in activation and/or memory. The generation of CD4' and CDS- T-cell responses against a target antigen is usually dependent upon in vivo priming, either through natural infection or through deliberate immunization.
As used in this specification. a "naive" T-cell is one that has not been exposed to foreign antigen (non-autologous) antigen or one that has not been exposed to cryptic autologous antigen. A "naive" T-cell is sometimes referred to as an "unprimed"
T-cell. The
3 skilled artisan will recognize that a "resting" cell is in the G~, phase of the cell cycle and hence is not dividing or undergoing mitosis. The skilled artisan will also recognize that an "anergic"
T-cell is one that is unable to function properly; i.e., such as a cell that lacks the ability to mediate the normal immune response. T-cells from diseased patients may contain T-cells that have been primed, but are anergic.
As used in this specification "memory T-cells," also known as "memory phenotype" T-cells, is used to designate a class of T-cells that have previously encountered a peptide antigen but are now resting and are capable of being activated. Memory T-cells are T-cells which have been exposed to antigen and then survive for extended periods in the body without the presence of stimulating antigen. However, these memory T-cells respond to "recall" antigens. In general, memory T-cells are more responsive to a "recall" antigen, when compared with the naive T-cell response to peptide antigen. Memory cells can be recognized by the presence of certain cell-surface antigens, such as CD45R0, CD58, CD1 la, CD29, CD44 and CD26, which are markers for differentiated T-cells.
As used in this specification. an "telomerase-specific" T-cell response is a T-cell response (for example, proliferative, c~-rtotoxic and/or cytokine secretion) to telomerase antigenic stimulus, for example a peptide. which is not evident with other stimuli, such as peptides with different amino acid sequences (control peptides). The responsiveness of the T-cell is measured by assessing the appearance of cell surface molecules that are characteristic of T-cell activation, including, but not limited to CD25 and CD69. Such assays are known in the art.
The term "treating" in its various grammatical forms in relation to the present invention refers to preventing, curing, reversing, attenuating, alleviating, minimizing, suppressing or halting the deleterious effects of a disease state, disease progression, disease causative agent or other abnormal condition.
T-cell is one that is unable to function properly; i.e., such as a cell that lacks the ability to mediate the normal immune response. T-cells from diseased patients may contain T-cells that have been primed, but are anergic.
As used in this specification "memory T-cells," also known as "memory phenotype" T-cells, is used to designate a class of T-cells that have previously encountered a peptide antigen but are now resting and are capable of being activated. Memory T-cells are T-cells which have been exposed to antigen and then survive for extended periods in the body without the presence of stimulating antigen. However, these memory T-cells respond to "recall" antigens. In general, memory T-cells are more responsive to a "recall" antigen, when compared with the naive T-cell response to peptide antigen. Memory cells can be recognized by the presence of certain cell-surface antigens, such as CD45R0, CD58, CD1 la, CD29, CD44 and CD26, which are markers for differentiated T-cells.
As used in this specification. an "telomerase-specific" T-cell response is a T-cell response (for example, proliferative, c~-rtotoxic and/or cytokine secretion) to telomerase antigenic stimulus, for example a peptide. which is not evident with other stimuli, such as peptides with different amino acid sequences (control peptides). The responsiveness of the T-cell is measured by assessing the appearance of cell surface molecules that are characteristic of T-cell activation, including, but not limited to CD25 and CD69. Such assays are known in the art.
The term "treating" in its various grammatical forms in relation to the present invention refers to preventing, curing, reversing, attenuating, alleviating, minimizing, suppressing or halting the deleterious effects of a disease state, disease progression, disease causative agent or other abnormal condition.
4 B. Telomerase Antigens 1. Generally Useful Antigens Telomerase antigens according to the invention share the characteristic ability to generate a specific T-cell response. This response may be either class I-or class II-specific.
In one aspect, this response is MHC class I-specific, and will comprise antigen- and MHC-restricted cytotoxicity. Class I molecules include HLA-A, HLA-B and HLA-C.
Thus, preferred antigens bind class I molecules, e.g., HLA-Al, HLA-A2, HLA-A3 or HLA-Al 1.
More preferred antigens bind all class I molecules. In contrast, where class II-specific (e.g., helper fimetions) responses are desired, class-II-binding antigens will be used. Class II
molecules include HLA-DR, HLA-DQ and HLA-DP. Useful antigens can be determined as set out below.
Telomerase antigens are typically derived from the sequence of the protein portion of telomerase, which is disclosed in U.S. Patent No. 5,837,857 ( 1998) and at GenBank Accession Nos. AF015950 and AFOI 8167, which sequences are hereby incorporated by reference. They may be made, for example. by proteolytic digestions of the telomerase protein and/or by recombinant DNA means. Generally, the relatively short peptide versions will be prepared by synthetic means.
Although telomerase antigens according to the invention are not limited by size, and they may be a portion or even all of the telomerase protein, they are usually small peptide antigens. A small size is preferred, due to ease of manufacture and greater specificity.
Accordingly, unless they are multimeric (i.e., multiple copies of the same epitope) most telomere antigens will be less than about 50 amino acids in length. Preferred antigens are less than about 25 amino acids in length, with other preferred antigens being between about 8 to about 12 amino acids long, although sequences as short as 6 or 7 amino acids are contemplated. Nine-mers are typical of class I antigens, since they usually retain the requisite functional character; they include Ile-Leu-Ala-Lys-Phe-Leu-His-Trp-Leu (ILAKFLHWL) as a preferred species.
In one aspect, this response is MHC class I-specific, and will comprise antigen- and MHC-restricted cytotoxicity. Class I molecules include HLA-A, HLA-B and HLA-C.
Thus, preferred antigens bind class I molecules, e.g., HLA-Al, HLA-A2, HLA-A3 or HLA-Al 1.
More preferred antigens bind all class I molecules. In contrast, where class II-specific (e.g., helper fimetions) responses are desired, class-II-binding antigens will be used. Class II
molecules include HLA-DR, HLA-DQ and HLA-DP. Useful antigens can be determined as set out below.
Telomerase antigens are typically derived from the sequence of the protein portion of telomerase, which is disclosed in U.S. Patent No. 5,837,857 ( 1998) and at GenBank Accession Nos. AF015950 and AFOI 8167, which sequences are hereby incorporated by reference. They may be made, for example. by proteolytic digestions of the telomerase protein and/or by recombinant DNA means. Generally, the relatively short peptide versions will be prepared by synthetic means.
Although telomerase antigens according to the invention are not limited by size, and they may be a portion or even all of the telomerase protein, they are usually small peptide antigens. A small size is preferred, due to ease of manufacture and greater specificity.
Accordingly, unless they are multimeric (i.e., multiple copies of the same epitope) most telomere antigens will be less than about 50 amino acids in length. Preferred antigens are less than about 25 amino acids in length, with other preferred antigens being between about 8 to about 12 amino acids long, although sequences as short as 6 or 7 amino acids are contemplated. Nine-mers are typical of class I antigens, since they usually retain the requisite functional character; they include Ile-Leu-Ala-Lys-Phe-Leu-His-Trp-Leu (ILAKFLHWL) as a preferred species.
5
6 PCT/IB00/00610 Variants of telomerase antigens are also contemplated. It is only important that any variants retain the functional characteristics of a telomerase antigen: ( 1 ) the ability to bind an MHC molecule, e.g., HLA-A2, and (2) the ability to induce a telomerase specific T-cell response. Amino acid substitutions, i.e. "conservative substitutions" that yield "conservative variants," may be made, for instance, on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.
For example: (a) nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; (b) polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; (c) positively charged (basic) amino acids include arainine, lysine, and histidine; and (d) negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Substitutions typically may be made within groups (a)-(d). In addition, glycine and proline may be substituted for one another based on their relatively small sizes and lack of side-chains.
Similarly, certain amino acids, such as alanine, cysteine, leucine, methionine, glutamic acid, glutamine, histidine and lysine are more commonly found in a-helices, while valine, isoleucine, phenylalanine, tyrosine, tn~ptophan and threonine are more commonly found in (3-pleated sheets. Glycine, serine, aspartic acid, asparagine, and proline are commonly found in turns. The importance or substitution groups based on structure, of course, increases with the length of the antigen.
Some preferred conservative substitutions may be made among the following groups: (i) S and T; (ii) P and G; and (iii) A. ~', L and I. Given the known genetic code, and recombinant and synthetic DNA techniques. the skilled scientist readily can construct DNAs encoding the conservative amino acid variants. Of course, smaller variants may be synthesized. One such genus of consen~ative HLA-A2-binding variants includes peptides of the structure: (A/V/L/I)(A/V/L/I)(A/V/L/I)(A/V L; I)KF(A/V/L/I)HW(A/V/L/I). Thus, some preferred conservative variants include LLAhFLHWL, ILAKFLHWI, IIAKFLHWL, IIAKFLHWI, ILARFLHWL, and ILVKFLHWL, and permutations thereof, so long as the requisite functional characteristics are retained.
Moreover, one or more of the amino acids of the foregoing HLA-A2-binding peptides may be replaced with glycine. Parker et al., J. Immunol. 149:3580-87 (1992) disclose that up to six amino acids in a nine-mer may be replaced with glycine; thus, GLFGGGGGV can bind HLA-A2. The onlv real conservation observed in 9-mer HLA-A2-binding peptides was an Ile or a Leu at about position 2 (counting N- to C-terminal) and a Val or a Leu at about position 9. Some simple variants, therefore, include GLAKFLHWL, ILAGFLHWL, ILAKGLHWL, ILAKFGH~t'L, ILAKFLGWL and ILAKFLHGL, subject to the presence of the requisite functional characteristics.
An important source for guidance in regard to designing class I and class II
antigens, and in making conservative substitutions is Rammensee et al., Immunogenetics 41:178-228 (1995), which is hereby incorporated by reference in its entirety.
As indicated in the Rammensee reference, the motifs for both class I and class II molecules have certain "anchor" residues, that retain high degrees of conservation. For instance, HLA-A0201 (an HLA-A2 molecule), which is the molecule that the telomerase peptide ILAKFLHWL
was designed to bind (and does bind), has anchor residues at positions 2 and 9, corresponding to the conservative positions noted above. This molecule also has an "auxiliary"
position at 6, the relative conservation of which is important, but less so than the anchor residues. Thus, using the general guidance of Rammensee, the artisan will appreciate that, while the anchor residues and auxiliary residues are relatively conserved in HLA binding, the remainder of the antigen can vary widely, and is probably responsible for the particular antigenic character of the antigen, i.e., it differentiates telomerase from non-telomerase.
Other substitutions include replacing L-amino acids with the corresponding D-amino acids. This rationale, moreover can be combined with the foregoing conservative substitution rationales. For example, D-leucine may be substituted for L-isoleucine. In addition, these D-amino acid-containing peptides may be prepared which have an inverse sequence, relative to the
For example: (a) nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; (b) polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; (c) positively charged (basic) amino acids include arainine, lysine, and histidine; and (d) negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Substitutions typically may be made within groups (a)-(d). In addition, glycine and proline may be substituted for one another based on their relatively small sizes and lack of side-chains.
Similarly, certain amino acids, such as alanine, cysteine, leucine, methionine, glutamic acid, glutamine, histidine and lysine are more commonly found in a-helices, while valine, isoleucine, phenylalanine, tyrosine, tn~ptophan and threonine are more commonly found in (3-pleated sheets. Glycine, serine, aspartic acid, asparagine, and proline are commonly found in turns. The importance or substitution groups based on structure, of course, increases with the length of the antigen.
Some preferred conservative substitutions may be made among the following groups: (i) S and T; (ii) P and G; and (iii) A. ~', L and I. Given the known genetic code, and recombinant and synthetic DNA techniques. the skilled scientist readily can construct DNAs encoding the conservative amino acid variants. Of course, smaller variants may be synthesized. One such genus of consen~ative HLA-A2-binding variants includes peptides of the structure: (A/V/L/I)(A/V/L/I)(A/V/L/I)(A/V L; I)KF(A/V/L/I)HW(A/V/L/I). Thus, some preferred conservative variants include LLAhFLHWL, ILAKFLHWI, IIAKFLHWL, IIAKFLHWI, ILARFLHWL, and ILVKFLHWL, and permutations thereof, so long as the requisite functional characteristics are retained.
Moreover, one or more of the amino acids of the foregoing HLA-A2-binding peptides may be replaced with glycine. Parker et al., J. Immunol. 149:3580-87 (1992) disclose that up to six amino acids in a nine-mer may be replaced with glycine; thus, GLFGGGGGV can bind HLA-A2. The onlv real conservation observed in 9-mer HLA-A2-binding peptides was an Ile or a Leu at about position 2 (counting N- to C-terminal) and a Val or a Leu at about position 9. Some simple variants, therefore, include GLAKFLHWL, ILAGFLHWL, ILAKGLHWL, ILAKFGH~t'L, ILAKFLGWL and ILAKFLHGL, subject to the presence of the requisite functional characteristics.
An important source for guidance in regard to designing class I and class II
antigens, and in making conservative substitutions is Rammensee et al., Immunogenetics 41:178-228 (1995), which is hereby incorporated by reference in its entirety.
As indicated in the Rammensee reference, the motifs for both class I and class II molecules have certain "anchor" residues, that retain high degrees of conservation. For instance, HLA-A0201 (an HLA-A2 molecule), which is the molecule that the telomerase peptide ILAKFLHWL
was designed to bind (and does bind), has anchor residues at positions 2 and 9, corresponding to the conservative positions noted above. This molecule also has an "auxiliary"
position at 6, the relative conservation of which is important, but less so than the anchor residues. Thus, using the general guidance of Rammensee, the artisan will appreciate that, while the anchor residues and auxiliary residues are relatively conserved in HLA binding, the remainder of the antigen can vary widely, and is probably responsible for the particular antigenic character of the antigen, i.e., it differentiates telomerase from non-telomerase.
Other substitutions include replacing L-amino acids with the corresponding D-amino acids. This rationale, moreover can be combined with the foregoing conservative substitution rationales. For example, D-leucine may be substituted for L-isoleucine. In addition, these D-amino acid-containing peptides may be prepared which have an inverse sequence, relative to the
7 native sequence. Hence, ILAKFLHWL becomes LWHLFKALI. Such "retro-inverso"
peptides are expected to have improved properties. such as increased in vivo half life.
This translates into smaller doses and more economically viable production.
Some embodiments contemplate multimers of the foregoing peptides.
Multimers can contain multiple copies of the same peptide, or they can be mixed and matched. The multimers can be direct tandem repeats, and may contain short spacers sequences of amino acids (e.g., 2-5 residues) like Gly and/or Pro, or other suitable spacers.
Multimers may be any length, but typically will be less than about 100 amino acids. Preferred multimers are less than about 60 amino acids and have between about 2 and 5 copies of peptides of about 8 to about 12 amino acids long. Multimers may also comprise several different telomerase antigens.
The telomerase antigens may be glycosylated or partially glycosylated according to methods known in the art. They also can be modified with large molecular weight polymers, such as polyethylene glycols. In addition, lipid modifications are preferred IS because they may facilitate the encapsulation or interaction of the derivative with liposomes.
Exemplary lipid moieties useful for this purpose include, but are not limited to, palmitoyl, myristoyl, stearoyl and decanoyl groups or. more generally, any C, to C3o saturated, monounsaturated or polyunsaturated fatty acv) group.
For convenience in making chemical modifications, it is sometimes useful to include in a telomerase antigen one or more amino acids having a side chain amenable to modification. A preferred amino acid is lysine, which may readily be modified at the E-amino group. Side-chain carboxyls of aspartate and glutamate are readily modified, as are serine, threonine and tyrosine hydroxyl groups, the cysteine sulfhydryl group and the histidine amino group. The introduction of two cysteine residues. at spaced locations in a peptide antigen, may sen~e to form a structural constraint through a disulfide bridge, which may improve binding to MHC molecules.
Also illustrative of a telomerase antigen within the present invention is a non-peptide "mimetic," i.e., a compound that mimics one or more functional characteristics of the telomerase antigen. Mimetics are generally water-soluble, resistant to proteolysis, and non-immunogenic. Conformationally restricted, cyclic organic peptides which mimic telomerase antigens can be produced in accordance with known methods described, for example, by Saragovi, et al.. Science 253: 792 (1991).
Telomerase antigens may also be constructed as hybrids (and/or formulated as distinct molecules together in liposomes, as described below) with immune-stimulatory molecules, like cytokines and adjuvants. Interleukin-2 (IL-2) is one such cytokine. Other cytokines include GM-CSF, IL-12 and flt-3 ligand. Telomerase antigens may be made as fusion proteins with IL-2, for example, by recombinant DNA or chemical synthetic means, or they may made as chemical conjugates using bi-functional chemical linkers. It is anticipated that such chimeric proteins would possess an increased ability to generate a T-cell-specific response against telomerase. Adjuvants include monophosphoryl lipid A (MPLA), and derivatives thereof, which also may be attached to a telomerase antigen by conventional linkers. Other conventional immune stimulatory molecules include keyhole limpet hemocyanin (KLH).
2. Identification of Other Useful Antigens It is of interest to identify additional, and especially small telomerase antigens, which would be expected to generate a more specific response, associated with a particular epitope for example. Moreover, these small antigens may be more economically produced.
It is advantageous to identify additional telomerase antigen and further to refine the T-cell antigenicity of telomerase, even down to the epitopic level.
One classic method involves proteolytic treatment of the large antigen to derive smaller antigens. In addition, fragments of protein antigens can be produced by recombinant DNA
techniques and assayed to identify particular epitopes. Moreover, small peptides can be produced by in vitro synthetic methods and assayed.
As an alternative to the random approach of making parts of the intact antigen then assaying them, a more biologically relevant approach is possible.
Specifically, since antigenic fragments which bind to MHC class I and/or class II molecules, especially class I
molecules, are of particular importance, one exemplary approach is to isolate the MHC
molecules themselves and then to isolate the peptides associated with them.
For a general description of such a method, see PCT/US98%09288; Agrawal et al., Int'1 Immuno1.10:1907-16 ( 1998); and Agrawal et al., Cancer Res. ~ ~ :51 ~ 1-56 ( 1998).
In a typical method, either primary tumor cells or a cell line expressing the antigen of interest are provided. In addition. it will be recognized that phagocytic antigen presenting cells (or any APC), such as macrophages, may be fed large antigens (or portions thereof) and thus act as the starting material for these methods. The MHC
class I or class II
molecules can be isolated from these starting cells using known methods, such as antibody affinity (MHC-specific antibodies) and chromatographic techniques.
Isolated MHC molecules are then treated to release bound peptides. This may be accomplished by treatment with agents that disrupt the interactions between the bound peptide and the MHC molecule, for example. detergent, urea, guanidinium chloride, divalent cations, various salts and extremes in pH. The peptides released can be further purified using conventional chromatographic and antibody affinity (using antigen-specific antibody) methodologies. The purified peptides may then be subjected to sequence and structural determinations, using for example peptide sequencing, gas chromatography and/or mass spectroscopy.
In this mariner the sequences. structures of the most prevalent peptide epitopes associated with class I and/or class II molecules may be determined. Supplied with this sequence/structural information, permutations of the determined sequence can be made, as detailed above, and assayed using known T-cell assays. Rammensee et al., supra, provides extensive methods and guidance related to identifying both class I and class II motifs.
Yet another method of generating telomerase antigens may utilize algorithms known in the art for predicting binding sequences. Publicly available comparison programs using these algorithms to compare known peptide sequences to different HLA-binding motifs may be found, for example, at http://www-bimas.dcrt.nih.gov/hla bind.
Different class I and class II binding motifs may be found at that site or in publications like Rammensee et al. and Parker et al., both supra.
C. Vaccine Compositions In general, any telomerase-specific antigen, as described above, will be useful in formulating telomerase-specific vaccines. Preferred antigens may be associated with lipids, usually either by direct lipid modification of the antigen and/or by liposomal association, as described below. The antigens may be administered as peptides or peptide mimetics, or they may be administered in nucleic acid form.
1. Liposonaal Formulation In one embodiment of the in~~ention, the telomerase antigen is associated with a liposome. Techniques for preparation of iiposomes and the formulation of various molecules, including peptides, with liposomes (e.g., encapsulation or complex formation) are well known to the skilled artisan. Liposomes are microscopic vesicles that consist of one or more lipid bilayers surrounding aqueous compartments. See, generally, Bakker-Woudenberg et al.. Eur. .l. Clin. Microbiol. Infect. Dis. 12 (Suppl. I): S61 (1993) and Kim, Drugs 46: 618 (1993). Liposomes are similar in composition to cellular membranes and as a result, liposomes generally can be administered safely and are biodegradable.
Depending on the method of preparation, liposomes may be unilamellar or multilamellar, and can vary in size with diameters ranging from 0.02 ~m to greater than 10 pm. A variety of agents can be encapsulated in liposomes. Hydrophobic agents partition in the bilayers and hydrophilic agents partition within the inner aqueous space(s). See, for example, Machy et al., LIPOSOMES IN CELL BIOLOGY AND PHARMACOLOGY (dohn Libbey 1987), and Ostro et al., ( 1989) American J. Hosp. Pharnz. 46: 1576.
Liposomes can adsorb to virtually any type of cell and then release the encapsulated agent. Alternatively, the liposome fuses with the target cell, whereby the contents of the liposome empty into the target cell. Alternatively, an absorbed liposome may be endocytosed by cells that are phagocytic. Endocvtosis is followed by intralysosomal degradation of liposomal lipids and release of the encapsulated agents.
Scherphof et al., (1985) Ann. >\! Y. Acad. Sci. 446: 368.
Anionic liposomal vectors hare also been examined. These include pH
sensitive liposomes which disrupt or fuse with the endosomal membrane following endocytosis and endosome acidification. Among liposome vectors, however, cationic liposomes are the most studied, due to their effectiveness in mediating mammalian cell transfection in vitro.
Cationic lipids are not found in nature and can be cytotoxic, as these complexes appear incompatible with the physiological environment in vivo which is rich in anionic molecules. Liposomes are preferentially phagocytosed into the reticuloendothelial system. However, the reticuloendothelial system can be circumvented by several methods including saturation with large doses of liposome particles, or selective macrophage inactivation by pharmacological means. Classen et al., (1984) Biochinr.
Biophys. Acta 802:
428. In addition, incorporation of glycolipid- or polyethylene glycol-derivatised phospholipids into liposome membranes has been shown to result in a significantly reduced uptake by the reticuloendothelial system. Allen et al., (1991) Biochirn.
Biophys. Acta 1068:
133; Allen et al., (1993) Biochint. Biophys. .-lctcr 1150: 9.
Cationic liposome preparations can be made by conventional methodologies.
See, for example. Felgner et al., Pnoc. Nat'l .-1 cad. Sci USA 84:7413 ( 1987); Schreier, J. of Liposome Res. 2:145 (1992); Chang et al. ( 1988), supra. Commercial preparations, such as Lipofectin~ (Life Technologies, Inc., Gaithersburg, Maryland USA), also are available. The amount of liposomes and the amount of DICTA can be optimized for each cell type based on a dose response curve. Felgner et al., supra. For some recent reviews on methods employed see Wassef et al., Immunomethods 4: 217 - 222 ( 1994) and Weiner, A. L., Immunomethods 4:
217 - 222 ( 1994).
Other suitable liposomes that are used in the methods of the invention include multilamellar vesicles (MLV), oligolamellar vesicles (OLV), unilamellar vesicles (UV), small unilamellar vesicles (SUV), medium-sized unilamellar vesicles (MLJV), large unilamellar vesicles (LUV), giant unilamellar vesicles 1 GL~), multivesicular vesicles (MVV), single or oligolamellar vesicles made by reverse-phase evaporation method (REV), multilamellar vesicles made by the reverse-phase evaporation method (MLV-REV), stable plurilamellar vesicles (SPLV), frozen and thawed MLV (FATMLV), vesicles prepared by extrusion methods (VET), vesicles prepared by French press (FPV), vesicles prepared by fusion (FUV), dehydration-rehydration vesicles (DRV), and bubblesomes (BSV). The skilled artisan will recognize that the techniques for preparing these liposomes are well known in the art. See COLLOIDAL DRUG DELIVERY SYSTEMS, vol. 66 (1. Kreuter, ed., Marcel Dekker, Inc.
1994).
2. Suitable Adjuva~ats and Excipients The present vaccine formulations, liposomal or not, may be formulated advantageously with some type of adjuvant. As conventionally known in the art, adjuvants are substances that act in conjunction with specific antigenic stimuli to enhance the specific response to the antigen. MPLA, for example. has been shown to serve as an effective adjuvant to cause increased presentation of liposomal antigen by the APCs to specific T
Lymphocytes. Alving, C.R. 1993. Intmmaobiol. 187:430-446. Moreover, the skilled artisan will recognize that other such adjuvants, such as Detox, alum, QS21, complete and/or incomplete Freund's adjuvant, MDP, LipidA and derivatives thereof, are also suitable.
Another class of adjuvants include stimulatory cytokines, such as IL-2. Thus, the present vaccines may be formulated with IL-2 or IL-2 may be administered separately for optimal antigenic response. IL-2 is beneficially formulated with liposomes.
Vaccines may also be formulated with a pharmaceutically acceptable excipient.
Such excipients are well known in the art, but typically should be physiologically tolerable and inert or enhancing with respect to the vaccine properties of the inventive compositions.
Examples include liquid vehicles such as sterile, physiological saline. When using an excipient, it may be added at any point in formulating the vaccine or it may be admixed with the completed vaccine composition.
Vaccines may be formulated for multiple routes of administration. Specifically preferred routes include intramuscular, percutaneous, subcutaneous, or intradermal injection, aerosol, oral or by a combination of these routes, at one time, or in a plurality of unit dosages.
Administration of vaccines is well known and ultimately will depend upon the particular formulation and the judgement of the attending physician.
Vaccine formulations can be maintained as a suspension, or they may be lyophilized and hydrated later to generate a useable vaccine.
D. Targeting the Inventive Antigens and Vaccines In order to provide greater specificity, thus reducing the risk of toxic or other unwanted effects during in vivo administration, it is advantageous to target the inventive compositions to the cells through which they are designed to act, namely antigen-presenting cells. This may conveniently be accomplished using conventional targeting technology. One exemplary form of targeting using antibodies, or similar specifically-binding molecules, associated in some fashion with the antigen and/or vaccine composition.
Targeting molecules have the characteristic of being able to distinguish to some degree, target APCs over background. non-APCs. Targeting molecules include mannose and the Fc portion of antibodies, and the like. which will target antigen presenting cells. Targeting molecules may be directly associated with telomerase antigens, for example, by chemical conjugation or by fusion protein production, in the case of protein-based targeting sequences.
Due to their convenience and extensive familiarity in the art, antibodies and antibody derivatives are preferred targeting molecules. Antibodies and their derivatives include, but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies including single chain Fv (scFv) fragments, Fab fragments, F(ab'), fragments. fragments produced by a Fab expression library, epitope-binding fragments, and humanized forms of any of the above. Of course, the smaller versions of these molecules are preferred, based on the fact that they will more readily target to an APC.
In general, techniques for preparing polyclonal and monoclonal antibodies as well as hybridomas capable of producing the desired antibody are well known in the art (Campbell, A.M., Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam, The Netherlands (1984); St.
Groth et al., J. Immunol. Methods 35:1-21 (1980); Kohler and Milstein, Nature 256:495-497 (1975)), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., Immunology Today 4:72 (1983); Cole et al.. in :hlonoclonul Antibodies and Cancer Tlzerapy, Alan R. Liss, Inc. (1985), pp. 77-96). Affinity of the antisera for the antigen may be determined by preparing competitive binding cur<~es, as described, for example, by Fisher, Chap. 42 in: Manual of Clinical Immasnoloy, second edition, Rose and Friedman, eds., Amer.
Soc. For Microbiology, Washington, D.C. ( 1980).
Fragments or derivatives of antibodies include any portion of the antibody which is capable of binding an APC target molecule, typically a surface antigen. Antibody fragments specifically include F(ab')=, Fab, Fab' and Fv fragments. These can be generated from any class of antibody, but typically are made from IgG or IgM. They may be made by conventional recombinant DNA techniques or. using the classical method, by proteolytic digestion with papain or pepsin. See CURRENT PROTOCOLS IN IMMUNOLOGY, chapter 2, Coligan et al., eds., (John Wiley & Sons 1991-92).
F(ab')2 fragments are typically about 110 kDa (IgG) or about 150 kDa (IgM) and contain two antigen-binding regions, joined at the hinge by disulfide bond(s).
Virtually all, if not all, of the Fc is absent in these fragments. Fab' fragments are typically about 55 kDa (IgG) or about 75 kDa (IgM) and can be formed, for example, by reducing the disulfide bonds) of an F(ab')2 fragment. The resulting free sulfhydryl groupls) may be used to conveniently conjugate Fab' fragments to other molecules, such as telomerase antigens or adjuvant molecules.
Fab fragments are monovalent and usually are about 50 kDa (from any source).
Fab fragments include the light (L) and heavy (H) chain, variable (VL and VH, respectively) and constant (CL CH, respectively) regions of the antigen-binding portion of the antibody. The H and L
portions are linked by one or more intramolecular disulfide bridges.
Fv fragments are typically about 25 kDa (regardless of source) and contain the variable regions of both the light and heavy chains (VL and VH, respectively).
Usually, the VL and VH chains are held together only by non-covalent interactions and, thus, they readily dissociate.
They do, however, have the advantage of small size and they retain the same binding properties of the larger Fab fragments. Accordingly, methods have been developed to crosslink the VL and VH
chains, using, for example, glutaraldehyde (or other chemical crosslinkers), intermolecular disulfide bonds (by incorporation of cysteines) and peptide linkers. The resulting Fv is now a single chain (i.e., scFv).
Other antibody derivatives include single chain antibodies (U.S. Patent 4,946,778;
Bird, Science 242:423-426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA
85:5879-5883 (1988);
and Ward et al., Nature 334:544-546 ( 1989)). Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain FV (scFv).
Derivatives also include "chimeric antibodies" (Morrison et al., Proc. Natl.
Acad. Sci., 81:6851-6855 (1984); Neuberger et crl., Nata~re, 312:604-608 (1984); Takeda et al., Nature, 314:452-454 (1985)). These chimeras are made by splicing the DNA
encoding a mouse antibody molecule of appropriate specificity with, for instance, DNA
encoding a human antibody molecule of appropriate specificity. Thus, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.
Recombinant molecules having a human framework region and murine complementarity determining regions (CDRs) also are made using well-known techniques. These are also known sometimes as "humanized" antibodies and they and chimeric antibodies or antibody fragments offer the added advantage of at least partial shielding from the human immune system. They are, therefore, particularly useful in therapeutic in vivo applications.
E. Nucleic Acid-Based Vaccines Recently, there has been increased interest in polynucleotide-based vaccines, and such applications are contemplated here. These vaccines generally rely on either a DNA
vector that encodes the antigen of interests under operable control of transcription and translation signals, or a RNA vector that encodes the antigen of interests under operable control of translation signals. When these vaccines are administered, they are thought to be taken up by the surrounding cells, which then express the target antigen. The expressed antigen apparently becomes associated with the cell's major histocompatability (MHC) antigens and are thus localized to the surface of the cell and presented to immune cells. See, for example, Corr et al., J. Exp. Med. 184: 1 »~-60 (1996). Such vaccines may employ naked DNA (Id.) or the DNA may be liposomally associated or trapped (Gregoriadis et al., FEBS Lett. 402: 107-10 ( 1997)).
These so-called "naked DNA' vaccines or vaccines comprising RNA have broad applicability. They may be employed, for example, as anti-cancer vaccines (Scheurs et al., Cancer Res. ~8: 2509-14 (1998); Hurpin et ul., Vaccine 16: 208-15 (1998)) and anti-viral vaccines (Bohm et al., Vaccine 16: 949-54 (1998); Lekutis et al., J. Immunol.
158: 4471-77 ( 1997)), among others. Naked DNA vaccines have been shown to elicit both class I- (Scheurs et al., supra; Bohm et al, supra; Hurpin et al, supra) and class II-restricted responses (Lekutis et cal., szzpra; Manickan et czl., J. Leukoc. Biol. 61: 125-32 (1997))).
Accordingly, any of the foregoing telomerase antigens may be administered as a naked DNA vaccine. These vaccines will comprise a nucleic acid vector that encodes a telomerase antigen under the control of transcription and translation signals that operate in a mammal, preferably a human. They may be administered associated with or encapsulated by (usually cationic) liposomes, as detailed above, or they may be administered in any other physiologically tolerable excipient.
F. Methods of the Invention According to one aspect of the invention, the foregoing telomerase antigens (or vaccine compositions) may be used as a conventional vaccine directly to induce an immune response against telomerase. In some cases, however, for an improved therapeutically or prophylactically suitable T-cell response, the antigen may be liposome-associated, as indicated above.
Since telomerase is expressed at high levels in cancer cells, the present antigens and vaccines are particularly suited for methods of treating and/or preventing cancer.
A representative method involves administering to a cancer patient an effective amount of one or more of the foregoing telomerase antigens. which may be formulated as a vaccine. Again, smaller peptide antigens are preferred.
In addition, it is contemplated that the present telomerase antigens and vaccines will be particularly useful in ex vino techniques. In general, these techniques entail isolating cells from a patient, contacting them with a telomerase antigen (or a vaccine, including nucleic acid vaccines) and administering the contacted cells back to the patient. In some cases (subject, for example, to MHC matching) the cells may be taken from one patient for administration to another.
In one embodiment, autologous or compatible antigen presenting cells (usually dendritic cells or peripheral blood lymphocwtes) are primed ex vivo, with a telomerase antigen.
These "telomerase-primed" cells may then be transferred in beneficial amounts into a patient in need of therapy or prophylaxis. As with all aspects of the invention, the ex vivo priming step may be accomplished using lipid- and or liposome-associated small peptide antigen.
Yet another adoptive approach is contemplated, whereby antigen presenting cells are generated, as above, and used to generate autologous or compatible T-cells effectors ex vivo. T-cells so generated may be adoptively transferred in beneficial amounts to a patient in need. For a description of art-recognized techniques for adoptive T-cell transfer therapy, see Bartels, et al. Annals of Surgical Oncology, 3(1):67 (1996), which is hereby incorporated by reference.
Co-treatment with other immunostimmulatory, listed above, is also contemplated. Molecules like IL-2, GM-CSF, IL-12, flt-3 ligand, CD 40, and the like, are envisioned as quite useful. IL-2, for example. may be administered concurrently, separately or in a combined formulation, or it may be administered in an alternative dosing regime with the telomerase antigen or vaccine. In a one method, the IL-2 is formulated with liposomes.
In a further embodiment of the invention, any of the foregoing antigens or vaccines may be used in conjunction with known anti-cancer agents. One example includes MUC-1-based therapeutics. Numerous additional examples of these are well-known in the art Conventional chemotherapeutic agents include alkylating agents, antimetabolites, various natural products (e.g., vinca alkaloids, epipodophyllotoxins, antibiotics, and amino acid-depleting enzymes), hormones and hormone antagonists. Specific classes of agents include nitrogen mustards, alkyl sulfonates, nitrosoureas. triazenes, folic acid analogues, pyrimidine analogues, purine analogs, platinum complexes, adrenocortical suppressants, adrenocorticosteroids, progestins, estrogens, antiestrogens and androgens.
Some exemplary compounds include cyclophosphamide, chlorambucil, methotrexate, fluorouracil, cytarabine, thioguanine, vinblastine, vincristine, doxorubincin, daunorubicin, mitomycin, cisplatin, hydroxyurea, prednisone, hydroxyprogesterone caproate, medroxyprogesterone, megestrol acetate, diethyl stilbestrol, ethinyl estradiol. tomoxifen, testosterone propionate and fluoxymesterone.
A therapeutically or prophylactically beneficial or effective amount is an amount sufficient to induce a clinically relevant telomerase-specific T-cell response, as defined above. Clinical relevance can be determined by clinician.
Administration may be by any number of routes, including parenteral and oral.
Cell-based vaccines are advantageously administered intravenously. Other vaccines typically will be administered intramuscularly, intradermally, subcutaneously or orally.
The skilled artisan will recognize that the route of administration will vary depending on the nature of the vaccine formulation. Determining the optimal route of vaccination may be determined empirically and is well within the level of ordinary skill in the art.
Nucleic acid vaccines may also be administered by a variety of routes, the optimal route being determined empirically. For instance, some antigens have been found to elicit a superior cytotoxic response when administered intravenously. Hurpin et al, sarpra.
For a superior immune response to oral administration, it may be advantageous to co-administer with the vaccine a mucosal adjuvant, like cholera toxin or cationic lipids. Ethchart et al., J. Gen. Virol. 78: 1577-80 (1997). Intramuscular, intradermal and subcutaneous administration are also preferred.
EXA_VIPLES
This example illustrates the use of the telomerase-specific peptides to generate an antigen-specific cytotoxic T-cell response.
A. Materials and Methods In general, PCT/US98/09288; Agrawal et al., Int'1 Immuno1.10:1907-16 (1998); and Agrawal et al., Cancer Res. ~~:~ 1 ~ 1-~6 (1998) provide suitable methods, and those disclosures are hereby incorporated by reference, in their entirety.
Peptides. Peptides were selected using the HLA peptide search program at http://www-bimas.dcrt.nih.gov. HLA-A2 specificity was selected, with default parameters.
Three of the top twenty scores were synthesized and tested. These peptides has the sequences: RLVDDFLLV, ELLRSFFYV and ILAKFLHWL.
Preparation of Liposomes. The bulk liquid composition of liposomes consisted of dipalmitoyl phosphatidyl choline (DPPC), cholesterol (Chol) and dimyristoyl phosphatidyl glycerol (DMPG) in a molar ratio of 3:1:0.2 and contained Lipid A at a concentration of 1%
(w/w) of bulk lipid. Synthetic telomerase peptides were present in the aqueous phase during liposome formation at a concentration of 0.7 mgiml, and approximately 28% of the input peptide was captured within the liposome structures. The formulated product contained 2 mg of bulk lipid, 20 ~g Lipid A and about 20 ~g of peptide per injected dose of 100 ~l.
Bulk lipids and Lipid A were dissolved in chloroform/methanol (methanol was used initially to solubilize DMPG). The lipid mixturefor each 4 ml preparationof liposomes consisted of 64 mg DPPC, 11 mg Chol, 5 my DMPG, 0.8 mg Lipid A in 12 ml of chloroform/methanol in amolar ratio of 3:1:0.25 at a final lipid concentration of 30 mM. Each 12 ml of the lipid mixture was dried to a film by rotary evaporation at 53°C in a 250 ml round bottom flask, and residual solvent was removed under high vacuum. The lipid film was hydrated by addition of 4 ml PBS containing the peptide and slow rotation of the flasks at 53°C followed by 5 cycles of vortexing and warming to 53°C.
Liposome structures were reformed to a more uniform size by a series of 5 freeze/thaw cycles consisting of freezing in a dry ice bath, thawing, warming to 41 °C and vortexing before beginning the next cycle. Liposomes then were collected by ultracentrifugation at 1500,000 x g at 4°C for 20 minutes, washed twice by addition of PBS
and ultracentrifugation again. Liposomes were finally reconstituted to the desired volume.
Cytokines. In order to promote CTL generation, human recombinant cytokines, IL-12 (R&D Systems, Minneapolis. MN), IL-7 (Intermedico, Markham, Ontario) were diluted in serum-free AIM-V media (Life Technologies) just prior to use.
Genercal Procedttresrfor Loacfrng APCs with Liposonae-encapsulated peptide.
Human peripheral blood lymphocytes (PBLs) were purified from heparinized blood by centrifugation in Ficoll-Hypaque (Pharmacia. Uppsala, Sweden). The Ficoll-blood interface layer obtained by centrifugation was collected and washed twice with RPMI
before use.
Briefly, to 2-10x106 PBLs in 0.9 mL AIM-V media, one dose of liposome containing peptide formulation was added and the PBLs were incubated overnight at 37°C
with CO, supplemented incubator. After incubation, the PBLs were treated with mitomycin C
or y-irradiated (3000 rads) followed by washing v;~ith AIM-V media.
Cvtotoxic T Ivmphocvte assaus. For the CTL assay, three (HLA.A2+) normal donors' PBLs were used. The T-cells were Grown for five weeks in bulk cultures as described above. At the end of two weeks, live T-cells were harvested from flasks and counted. The targets were mutant T2 cells. Houbiers et al., Eur. J. Immunol 23:2072-2077 (1993); Stauss et al., Proc. Natl. Acad. Sci. U.S.A. 89:7871-787 (1992). The telomerase peptide-mediated upregulation of HLA.A2 expression on T2 cells was examined using the HLA-A2-associated peptides ILAKFLHWL (BPl-187), RLVDDFLLV (BP1-190), and ELLRSFFYV (BP1-191) using known methods. Townsend et al., Nature 346:476 (1989). T2 cells were loaded overnight at 37°C in 7% CO, with various the telomerase synthetic peptides at 200 pM in presence of 8 yg exogenous (32 microglobulin. Houbiers et al., supra; Stauss et al., supra.
The peptide-loaded T2 target cells were loaded with''Cr (using NaCrO~) for 90 minutes and washed. CTL assays were performed as pre~~iously described. Agrawal et al., J.
Immunol.
156:2089 (1996). Percent specific killing was calculated as: experimental release -spontaneous release/maximum release - spontaneous release x 100. The effector versus target ratios used were 50:1, 25:1, 10:1 and S:l . Each group was set up in four replicate and mean percent specific killing was calculated.
Cell Sz~r~'ace Immuno~la~orescence Staining. For detection of cell surface antigens, the peptide-fed T2 cells were washed once in cold PBS containing I%
BSA
followed by addition of 1 pg of anti-A2 monoclonal antibody, .MA2.1 or a control antibody and incubated for 45 minutes on ice. Cells were then washed and a secondary antibody, goat anti-mouse IgG (H+L)-FITC labeled (Southern Biotech) was added for 30 minutes on ice.
B. Results Using the foregoing methods, the cytotoxic activity of T-cells stimulated with autologous APCs pulsed with liposomal telomerase peptide was determined. The source of T-cells was PBLs from three HLA.A2' donors. Target T2 cells (HLA.A2+) were loaded with the telomerase peptide indicated above.
The negative control was T2 cells, and the positive control was the 10-mer flu peptide FLPSDYFPSV, which strongly upreQulates HLA.A2 expression on T2 cells.
These data confirm that the present methods can be used to generate specific, biologically relevant T-cell responses to telomerase, such as cytotoxicity.
Figure 1 shows FACS analysis of cells treated according to the foregoing methods, panel A shows the negative control. Panel B, is the positive control, showing a 227% increase in median channel intensity of A2 expression as compared to the negative control. Panel C, is the experimental with BPl-187, and shows a 396% increase in median channel intensity of A2 expression as compared to the negative control. Panels D and E show the results with BPl-190 and BPl-191, respectively yielding 0% and 6%
increases over the negative control.
Table I shows specific killing of targets by telomerase antigen-primed (BP1-187) cytotoxic T-cells. The negative control was SIINFEKL.
These data indicate that, contrary to expectations, an immune response can be generated against telomerase, a self antigen.
Table I: Telomerase Peptide-Specific Killing TARGET EFFECTOR:T.aRGET RATIO PERCENT KILLING
Unloaded X0:1 35.7 Unloaded 25:1 23.8 Unloaded 10:1 13.1 Unloaded 5:1 5.0 Telomerase Peptide-Loaded50:1 56.7 Telomerase Peptide-Loaded25:1 33.5 Telomerase Peptide-Loaded10:1 21.1 Telomerase Peptide-Loaded5:1 15.5 Control Peptide-Loaded X0:1 32.3 Control Peptide-Loaded 25:1 22.1 Control Peptide-Loaded 10:1 11.3 Control Peptide-Loaded ~:1 7.6 *******
The foregoing detailed description and examples are presented for illustrative purposes only and are not meant to be limiting. Further embodiments of the invention will be ready apparent to the skilled worker in view of this disclosure.
?5
peptides are expected to have improved properties. such as increased in vivo half life.
This translates into smaller doses and more economically viable production.
Some embodiments contemplate multimers of the foregoing peptides.
Multimers can contain multiple copies of the same peptide, or they can be mixed and matched. The multimers can be direct tandem repeats, and may contain short spacers sequences of amino acids (e.g., 2-5 residues) like Gly and/or Pro, or other suitable spacers.
Multimers may be any length, but typically will be less than about 100 amino acids. Preferred multimers are less than about 60 amino acids and have between about 2 and 5 copies of peptides of about 8 to about 12 amino acids long. Multimers may also comprise several different telomerase antigens.
The telomerase antigens may be glycosylated or partially glycosylated according to methods known in the art. They also can be modified with large molecular weight polymers, such as polyethylene glycols. In addition, lipid modifications are preferred IS because they may facilitate the encapsulation or interaction of the derivative with liposomes.
Exemplary lipid moieties useful for this purpose include, but are not limited to, palmitoyl, myristoyl, stearoyl and decanoyl groups or. more generally, any C, to C3o saturated, monounsaturated or polyunsaturated fatty acv) group.
For convenience in making chemical modifications, it is sometimes useful to include in a telomerase antigen one or more amino acids having a side chain amenable to modification. A preferred amino acid is lysine, which may readily be modified at the E-amino group. Side-chain carboxyls of aspartate and glutamate are readily modified, as are serine, threonine and tyrosine hydroxyl groups, the cysteine sulfhydryl group and the histidine amino group. The introduction of two cysteine residues. at spaced locations in a peptide antigen, may sen~e to form a structural constraint through a disulfide bridge, which may improve binding to MHC molecules.
Also illustrative of a telomerase antigen within the present invention is a non-peptide "mimetic," i.e., a compound that mimics one or more functional characteristics of the telomerase antigen. Mimetics are generally water-soluble, resistant to proteolysis, and non-immunogenic. Conformationally restricted, cyclic organic peptides which mimic telomerase antigens can be produced in accordance with known methods described, for example, by Saragovi, et al.. Science 253: 792 (1991).
Telomerase antigens may also be constructed as hybrids (and/or formulated as distinct molecules together in liposomes, as described below) with immune-stimulatory molecules, like cytokines and adjuvants. Interleukin-2 (IL-2) is one such cytokine. Other cytokines include GM-CSF, IL-12 and flt-3 ligand. Telomerase antigens may be made as fusion proteins with IL-2, for example, by recombinant DNA or chemical synthetic means, or they may made as chemical conjugates using bi-functional chemical linkers. It is anticipated that such chimeric proteins would possess an increased ability to generate a T-cell-specific response against telomerase. Adjuvants include monophosphoryl lipid A (MPLA), and derivatives thereof, which also may be attached to a telomerase antigen by conventional linkers. Other conventional immune stimulatory molecules include keyhole limpet hemocyanin (KLH).
2. Identification of Other Useful Antigens It is of interest to identify additional, and especially small telomerase antigens, which would be expected to generate a more specific response, associated with a particular epitope for example. Moreover, these small antigens may be more economically produced.
It is advantageous to identify additional telomerase antigen and further to refine the T-cell antigenicity of telomerase, even down to the epitopic level.
One classic method involves proteolytic treatment of the large antigen to derive smaller antigens. In addition, fragments of protein antigens can be produced by recombinant DNA
techniques and assayed to identify particular epitopes. Moreover, small peptides can be produced by in vitro synthetic methods and assayed.
As an alternative to the random approach of making parts of the intact antigen then assaying them, a more biologically relevant approach is possible.
Specifically, since antigenic fragments which bind to MHC class I and/or class II molecules, especially class I
molecules, are of particular importance, one exemplary approach is to isolate the MHC
molecules themselves and then to isolate the peptides associated with them.
For a general description of such a method, see PCT/US98%09288; Agrawal et al., Int'1 Immuno1.10:1907-16 ( 1998); and Agrawal et al., Cancer Res. ~ ~ :51 ~ 1-56 ( 1998).
In a typical method, either primary tumor cells or a cell line expressing the antigen of interest are provided. In addition. it will be recognized that phagocytic antigen presenting cells (or any APC), such as macrophages, may be fed large antigens (or portions thereof) and thus act as the starting material for these methods. The MHC
class I or class II
molecules can be isolated from these starting cells using known methods, such as antibody affinity (MHC-specific antibodies) and chromatographic techniques.
Isolated MHC molecules are then treated to release bound peptides. This may be accomplished by treatment with agents that disrupt the interactions between the bound peptide and the MHC molecule, for example. detergent, urea, guanidinium chloride, divalent cations, various salts and extremes in pH. The peptides released can be further purified using conventional chromatographic and antibody affinity (using antigen-specific antibody) methodologies. The purified peptides may then be subjected to sequence and structural determinations, using for example peptide sequencing, gas chromatography and/or mass spectroscopy.
In this mariner the sequences. structures of the most prevalent peptide epitopes associated with class I and/or class II molecules may be determined. Supplied with this sequence/structural information, permutations of the determined sequence can be made, as detailed above, and assayed using known T-cell assays. Rammensee et al., supra, provides extensive methods and guidance related to identifying both class I and class II motifs.
Yet another method of generating telomerase antigens may utilize algorithms known in the art for predicting binding sequences. Publicly available comparison programs using these algorithms to compare known peptide sequences to different HLA-binding motifs may be found, for example, at http://www-bimas.dcrt.nih.gov/hla bind.
Different class I and class II binding motifs may be found at that site or in publications like Rammensee et al. and Parker et al., both supra.
C. Vaccine Compositions In general, any telomerase-specific antigen, as described above, will be useful in formulating telomerase-specific vaccines. Preferred antigens may be associated with lipids, usually either by direct lipid modification of the antigen and/or by liposomal association, as described below. The antigens may be administered as peptides or peptide mimetics, or they may be administered in nucleic acid form.
1. Liposonaal Formulation In one embodiment of the in~~ention, the telomerase antigen is associated with a liposome. Techniques for preparation of iiposomes and the formulation of various molecules, including peptides, with liposomes (e.g., encapsulation or complex formation) are well known to the skilled artisan. Liposomes are microscopic vesicles that consist of one or more lipid bilayers surrounding aqueous compartments. See, generally, Bakker-Woudenberg et al.. Eur. .l. Clin. Microbiol. Infect. Dis. 12 (Suppl. I): S61 (1993) and Kim, Drugs 46: 618 (1993). Liposomes are similar in composition to cellular membranes and as a result, liposomes generally can be administered safely and are biodegradable.
Depending on the method of preparation, liposomes may be unilamellar or multilamellar, and can vary in size with diameters ranging from 0.02 ~m to greater than 10 pm. A variety of agents can be encapsulated in liposomes. Hydrophobic agents partition in the bilayers and hydrophilic agents partition within the inner aqueous space(s). See, for example, Machy et al., LIPOSOMES IN CELL BIOLOGY AND PHARMACOLOGY (dohn Libbey 1987), and Ostro et al., ( 1989) American J. Hosp. Pharnz. 46: 1576.
Liposomes can adsorb to virtually any type of cell and then release the encapsulated agent. Alternatively, the liposome fuses with the target cell, whereby the contents of the liposome empty into the target cell. Alternatively, an absorbed liposome may be endocytosed by cells that are phagocytic. Endocvtosis is followed by intralysosomal degradation of liposomal lipids and release of the encapsulated agents.
Scherphof et al., (1985) Ann. >\! Y. Acad. Sci. 446: 368.
Anionic liposomal vectors hare also been examined. These include pH
sensitive liposomes which disrupt or fuse with the endosomal membrane following endocytosis and endosome acidification. Among liposome vectors, however, cationic liposomes are the most studied, due to their effectiveness in mediating mammalian cell transfection in vitro.
Cationic lipids are not found in nature and can be cytotoxic, as these complexes appear incompatible with the physiological environment in vivo which is rich in anionic molecules. Liposomes are preferentially phagocytosed into the reticuloendothelial system. However, the reticuloendothelial system can be circumvented by several methods including saturation with large doses of liposome particles, or selective macrophage inactivation by pharmacological means. Classen et al., (1984) Biochinr.
Biophys. Acta 802:
428. In addition, incorporation of glycolipid- or polyethylene glycol-derivatised phospholipids into liposome membranes has been shown to result in a significantly reduced uptake by the reticuloendothelial system. Allen et al., (1991) Biochirn.
Biophys. Acta 1068:
133; Allen et al., (1993) Biochint. Biophys. .-lctcr 1150: 9.
Cationic liposome preparations can be made by conventional methodologies.
See, for example. Felgner et al., Pnoc. Nat'l .-1 cad. Sci USA 84:7413 ( 1987); Schreier, J. of Liposome Res. 2:145 (1992); Chang et al. ( 1988), supra. Commercial preparations, such as Lipofectin~ (Life Technologies, Inc., Gaithersburg, Maryland USA), also are available. The amount of liposomes and the amount of DICTA can be optimized for each cell type based on a dose response curve. Felgner et al., supra. For some recent reviews on methods employed see Wassef et al., Immunomethods 4: 217 - 222 ( 1994) and Weiner, A. L., Immunomethods 4:
217 - 222 ( 1994).
Other suitable liposomes that are used in the methods of the invention include multilamellar vesicles (MLV), oligolamellar vesicles (OLV), unilamellar vesicles (UV), small unilamellar vesicles (SUV), medium-sized unilamellar vesicles (MLJV), large unilamellar vesicles (LUV), giant unilamellar vesicles 1 GL~), multivesicular vesicles (MVV), single or oligolamellar vesicles made by reverse-phase evaporation method (REV), multilamellar vesicles made by the reverse-phase evaporation method (MLV-REV), stable plurilamellar vesicles (SPLV), frozen and thawed MLV (FATMLV), vesicles prepared by extrusion methods (VET), vesicles prepared by French press (FPV), vesicles prepared by fusion (FUV), dehydration-rehydration vesicles (DRV), and bubblesomes (BSV). The skilled artisan will recognize that the techniques for preparing these liposomes are well known in the art. See COLLOIDAL DRUG DELIVERY SYSTEMS, vol. 66 (1. Kreuter, ed., Marcel Dekker, Inc.
1994).
2. Suitable Adjuva~ats and Excipients The present vaccine formulations, liposomal or not, may be formulated advantageously with some type of adjuvant. As conventionally known in the art, adjuvants are substances that act in conjunction with specific antigenic stimuli to enhance the specific response to the antigen. MPLA, for example. has been shown to serve as an effective adjuvant to cause increased presentation of liposomal antigen by the APCs to specific T
Lymphocytes. Alving, C.R. 1993. Intmmaobiol. 187:430-446. Moreover, the skilled artisan will recognize that other such adjuvants, such as Detox, alum, QS21, complete and/or incomplete Freund's adjuvant, MDP, LipidA and derivatives thereof, are also suitable.
Another class of adjuvants include stimulatory cytokines, such as IL-2. Thus, the present vaccines may be formulated with IL-2 or IL-2 may be administered separately for optimal antigenic response. IL-2 is beneficially formulated with liposomes.
Vaccines may also be formulated with a pharmaceutically acceptable excipient.
Such excipients are well known in the art, but typically should be physiologically tolerable and inert or enhancing with respect to the vaccine properties of the inventive compositions.
Examples include liquid vehicles such as sterile, physiological saline. When using an excipient, it may be added at any point in formulating the vaccine or it may be admixed with the completed vaccine composition.
Vaccines may be formulated for multiple routes of administration. Specifically preferred routes include intramuscular, percutaneous, subcutaneous, or intradermal injection, aerosol, oral or by a combination of these routes, at one time, or in a plurality of unit dosages.
Administration of vaccines is well known and ultimately will depend upon the particular formulation and the judgement of the attending physician.
Vaccine formulations can be maintained as a suspension, or they may be lyophilized and hydrated later to generate a useable vaccine.
D. Targeting the Inventive Antigens and Vaccines In order to provide greater specificity, thus reducing the risk of toxic or other unwanted effects during in vivo administration, it is advantageous to target the inventive compositions to the cells through which they are designed to act, namely antigen-presenting cells. This may conveniently be accomplished using conventional targeting technology. One exemplary form of targeting using antibodies, or similar specifically-binding molecules, associated in some fashion with the antigen and/or vaccine composition.
Targeting molecules have the characteristic of being able to distinguish to some degree, target APCs over background. non-APCs. Targeting molecules include mannose and the Fc portion of antibodies, and the like. which will target antigen presenting cells. Targeting molecules may be directly associated with telomerase antigens, for example, by chemical conjugation or by fusion protein production, in the case of protein-based targeting sequences.
Due to their convenience and extensive familiarity in the art, antibodies and antibody derivatives are preferred targeting molecules. Antibodies and their derivatives include, but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies including single chain Fv (scFv) fragments, Fab fragments, F(ab'), fragments. fragments produced by a Fab expression library, epitope-binding fragments, and humanized forms of any of the above. Of course, the smaller versions of these molecules are preferred, based on the fact that they will more readily target to an APC.
In general, techniques for preparing polyclonal and monoclonal antibodies as well as hybridomas capable of producing the desired antibody are well known in the art (Campbell, A.M., Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam, The Netherlands (1984); St.
Groth et al., J. Immunol. Methods 35:1-21 (1980); Kohler and Milstein, Nature 256:495-497 (1975)), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., Immunology Today 4:72 (1983); Cole et al.. in :hlonoclonul Antibodies and Cancer Tlzerapy, Alan R. Liss, Inc. (1985), pp. 77-96). Affinity of the antisera for the antigen may be determined by preparing competitive binding cur<~es, as described, for example, by Fisher, Chap. 42 in: Manual of Clinical Immasnoloy, second edition, Rose and Friedman, eds., Amer.
Soc. For Microbiology, Washington, D.C. ( 1980).
Fragments or derivatives of antibodies include any portion of the antibody which is capable of binding an APC target molecule, typically a surface antigen. Antibody fragments specifically include F(ab')=, Fab, Fab' and Fv fragments. These can be generated from any class of antibody, but typically are made from IgG or IgM. They may be made by conventional recombinant DNA techniques or. using the classical method, by proteolytic digestion with papain or pepsin. See CURRENT PROTOCOLS IN IMMUNOLOGY, chapter 2, Coligan et al., eds., (John Wiley & Sons 1991-92).
F(ab')2 fragments are typically about 110 kDa (IgG) or about 150 kDa (IgM) and contain two antigen-binding regions, joined at the hinge by disulfide bond(s).
Virtually all, if not all, of the Fc is absent in these fragments. Fab' fragments are typically about 55 kDa (IgG) or about 75 kDa (IgM) and can be formed, for example, by reducing the disulfide bonds) of an F(ab')2 fragment. The resulting free sulfhydryl groupls) may be used to conveniently conjugate Fab' fragments to other molecules, such as telomerase antigens or adjuvant molecules.
Fab fragments are monovalent and usually are about 50 kDa (from any source).
Fab fragments include the light (L) and heavy (H) chain, variable (VL and VH, respectively) and constant (CL CH, respectively) regions of the antigen-binding portion of the antibody. The H and L
portions are linked by one or more intramolecular disulfide bridges.
Fv fragments are typically about 25 kDa (regardless of source) and contain the variable regions of both the light and heavy chains (VL and VH, respectively).
Usually, the VL and VH chains are held together only by non-covalent interactions and, thus, they readily dissociate.
They do, however, have the advantage of small size and they retain the same binding properties of the larger Fab fragments. Accordingly, methods have been developed to crosslink the VL and VH
chains, using, for example, glutaraldehyde (or other chemical crosslinkers), intermolecular disulfide bonds (by incorporation of cysteines) and peptide linkers. The resulting Fv is now a single chain (i.e., scFv).
Other antibody derivatives include single chain antibodies (U.S. Patent 4,946,778;
Bird, Science 242:423-426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA
85:5879-5883 (1988);
and Ward et al., Nature 334:544-546 ( 1989)). Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain FV (scFv).
Derivatives also include "chimeric antibodies" (Morrison et al., Proc. Natl.
Acad. Sci., 81:6851-6855 (1984); Neuberger et crl., Nata~re, 312:604-608 (1984); Takeda et al., Nature, 314:452-454 (1985)). These chimeras are made by splicing the DNA
encoding a mouse antibody molecule of appropriate specificity with, for instance, DNA
encoding a human antibody molecule of appropriate specificity. Thus, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.
Recombinant molecules having a human framework region and murine complementarity determining regions (CDRs) also are made using well-known techniques. These are also known sometimes as "humanized" antibodies and they and chimeric antibodies or antibody fragments offer the added advantage of at least partial shielding from the human immune system. They are, therefore, particularly useful in therapeutic in vivo applications.
E. Nucleic Acid-Based Vaccines Recently, there has been increased interest in polynucleotide-based vaccines, and such applications are contemplated here. These vaccines generally rely on either a DNA
vector that encodes the antigen of interests under operable control of transcription and translation signals, or a RNA vector that encodes the antigen of interests under operable control of translation signals. When these vaccines are administered, they are thought to be taken up by the surrounding cells, which then express the target antigen. The expressed antigen apparently becomes associated with the cell's major histocompatability (MHC) antigens and are thus localized to the surface of the cell and presented to immune cells. See, for example, Corr et al., J. Exp. Med. 184: 1 »~-60 (1996). Such vaccines may employ naked DNA (Id.) or the DNA may be liposomally associated or trapped (Gregoriadis et al., FEBS Lett. 402: 107-10 ( 1997)).
These so-called "naked DNA' vaccines or vaccines comprising RNA have broad applicability. They may be employed, for example, as anti-cancer vaccines (Scheurs et al., Cancer Res. ~8: 2509-14 (1998); Hurpin et ul., Vaccine 16: 208-15 (1998)) and anti-viral vaccines (Bohm et al., Vaccine 16: 949-54 (1998); Lekutis et al., J. Immunol.
158: 4471-77 ( 1997)), among others. Naked DNA vaccines have been shown to elicit both class I- (Scheurs et al., supra; Bohm et al, supra; Hurpin et al, supra) and class II-restricted responses (Lekutis et cal., szzpra; Manickan et czl., J. Leukoc. Biol. 61: 125-32 (1997))).
Accordingly, any of the foregoing telomerase antigens may be administered as a naked DNA vaccine. These vaccines will comprise a nucleic acid vector that encodes a telomerase antigen under the control of transcription and translation signals that operate in a mammal, preferably a human. They may be administered associated with or encapsulated by (usually cationic) liposomes, as detailed above, or they may be administered in any other physiologically tolerable excipient.
F. Methods of the Invention According to one aspect of the invention, the foregoing telomerase antigens (or vaccine compositions) may be used as a conventional vaccine directly to induce an immune response against telomerase. In some cases, however, for an improved therapeutically or prophylactically suitable T-cell response, the antigen may be liposome-associated, as indicated above.
Since telomerase is expressed at high levels in cancer cells, the present antigens and vaccines are particularly suited for methods of treating and/or preventing cancer.
A representative method involves administering to a cancer patient an effective amount of one or more of the foregoing telomerase antigens. which may be formulated as a vaccine. Again, smaller peptide antigens are preferred.
In addition, it is contemplated that the present telomerase antigens and vaccines will be particularly useful in ex vino techniques. In general, these techniques entail isolating cells from a patient, contacting them with a telomerase antigen (or a vaccine, including nucleic acid vaccines) and administering the contacted cells back to the patient. In some cases (subject, for example, to MHC matching) the cells may be taken from one patient for administration to another.
In one embodiment, autologous or compatible antigen presenting cells (usually dendritic cells or peripheral blood lymphocwtes) are primed ex vivo, with a telomerase antigen.
These "telomerase-primed" cells may then be transferred in beneficial amounts into a patient in need of therapy or prophylaxis. As with all aspects of the invention, the ex vivo priming step may be accomplished using lipid- and or liposome-associated small peptide antigen.
Yet another adoptive approach is contemplated, whereby antigen presenting cells are generated, as above, and used to generate autologous or compatible T-cells effectors ex vivo. T-cells so generated may be adoptively transferred in beneficial amounts to a patient in need. For a description of art-recognized techniques for adoptive T-cell transfer therapy, see Bartels, et al. Annals of Surgical Oncology, 3(1):67 (1996), which is hereby incorporated by reference.
Co-treatment with other immunostimmulatory, listed above, is also contemplated. Molecules like IL-2, GM-CSF, IL-12, flt-3 ligand, CD 40, and the like, are envisioned as quite useful. IL-2, for example. may be administered concurrently, separately or in a combined formulation, or it may be administered in an alternative dosing regime with the telomerase antigen or vaccine. In a one method, the IL-2 is formulated with liposomes.
In a further embodiment of the invention, any of the foregoing antigens or vaccines may be used in conjunction with known anti-cancer agents. One example includes MUC-1-based therapeutics. Numerous additional examples of these are well-known in the art Conventional chemotherapeutic agents include alkylating agents, antimetabolites, various natural products (e.g., vinca alkaloids, epipodophyllotoxins, antibiotics, and amino acid-depleting enzymes), hormones and hormone antagonists. Specific classes of agents include nitrogen mustards, alkyl sulfonates, nitrosoureas. triazenes, folic acid analogues, pyrimidine analogues, purine analogs, platinum complexes, adrenocortical suppressants, adrenocorticosteroids, progestins, estrogens, antiestrogens and androgens.
Some exemplary compounds include cyclophosphamide, chlorambucil, methotrexate, fluorouracil, cytarabine, thioguanine, vinblastine, vincristine, doxorubincin, daunorubicin, mitomycin, cisplatin, hydroxyurea, prednisone, hydroxyprogesterone caproate, medroxyprogesterone, megestrol acetate, diethyl stilbestrol, ethinyl estradiol. tomoxifen, testosterone propionate and fluoxymesterone.
A therapeutically or prophylactically beneficial or effective amount is an amount sufficient to induce a clinically relevant telomerase-specific T-cell response, as defined above. Clinical relevance can be determined by clinician.
Administration may be by any number of routes, including parenteral and oral.
Cell-based vaccines are advantageously administered intravenously. Other vaccines typically will be administered intramuscularly, intradermally, subcutaneously or orally.
The skilled artisan will recognize that the route of administration will vary depending on the nature of the vaccine formulation. Determining the optimal route of vaccination may be determined empirically and is well within the level of ordinary skill in the art.
Nucleic acid vaccines may also be administered by a variety of routes, the optimal route being determined empirically. For instance, some antigens have been found to elicit a superior cytotoxic response when administered intravenously. Hurpin et al, sarpra.
For a superior immune response to oral administration, it may be advantageous to co-administer with the vaccine a mucosal adjuvant, like cholera toxin or cationic lipids. Ethchart et al., J. Gen. Virol. 78: 1577-80 (1997). Intramuscular, intradermal and subcutaneous administration are also preferred.
EXA_VIPLES
This example illustrates the use of the telomerase-specific peptides to generate an antigen-specific cytotoxic T-cell response.
A. Materials and Methods In general, PCT/US98/09288; Agrawal et al., Int'1 Immuno1.10:1907-16 (1998); and Agrawal et al., Cancer Res. ~~:~ 1 ~ 1-~6 (1998) provide suitable methods, and those disclosures are hereby incorporated by reference, in their entirety.
Peptides. Peptides were selected using the HLA peptide search program at http://www-bimas.dcrt.nih.gov. HLA-A2 specificity was selected, with default parameters.
Three of the top twenty scores were synthesized and tested. These peptides has the sequences: RLVDDFLLV, ELLRSFFYV and ILAKFLHWL.
Preparation of Liposomes. The bulk liquid composition of liposomes consisted of dipalmitoyl phosphatidyl choline (DPPC), cholesterol (Chol) and dimyristoyl phosphatidyl glycerol (DMPG) in a molar ratio of 3:1:0.2 and contained Lipid A at a concentration of 1%
(w/w) of bulk lipid. Synthetic telomerase peptides were present in the aqueous phase during liposome formation at a concentration of 0.7 mgiml, and approximately 28% of the input peptide was captured within the liposome structures. The formulated product contained 2 mg of bulk lipid, 20 ~g Lipid A and about 20 ~g of peptide per injected dose of 100 ~l.
Bulk lipids and Lipid A were dissolved in chloroform/methanol (methanol was used initially to solubilize DMPG). The lipid mixturefor each 4 ml preparationof liposomes consisted of 64 mg DPPC, 11 mg Chol, 5 my DMPG, 0.8 mg Lipid A in 12 ml of chloroform/methanol in amolar ratio of 3:1:0.25 at a final lipid concentration of 30 mM. Each 12 ml of the lipid mixture was dried to a film by rotary evaporation at 53°C in a 250 ml round bottom flask, and residual solvent was removed under high vacuum. The lipid film was hydrated by addition of 4 ml PBS containing the peptide and slow rotation of the flasks at 53°C followed by 5 cycles of vortexing and warming to 53°C.
Liposome structures were reformed to a more uniform size by a series of 5 freeze/thaw cycles consisting of freezing in a dry ice bath, thawing, warming to 41 °C and vortexing before beginning the next cycle. Liposomes then were collected by ultracentrifugation at 1500,000 x g at 4°C for 20 minutes, washed twice by addition of PBS
and ultracentrifugation again. Liposomes were finally reconstituted to the desired volume.
Cytokines. In order to promote CTL generation, human recombinant cytokines, IL-12 (R&D Systems, Minneapolis. MN), IL-7 (Intermedico, Markham, Ontario) were diluted in serum-free AIM-V media (Life Technologies) just prior to use.
Genercal Procedttresrfor Loacfrng APCs with Liposonae-encapsulated peptide.
Human peripheral blood lymphocytes (PBLs) were purified from heparinized blood by centrifugation in Ficoll-Hypaque (Pharmacia. Uppsala, Sweden). The Ficoll-blood interface layer obtained by centrifugation was collected and washed twice with RPMI
before use.
Briefly, to 2-10x106 PBLs in 0.9 mL AIM-V media, one dose of liposome containing peptide formulation was added and the PBLs were incubated overnight at 37°C
with CO, supplemented incubator. After incubation, the PBLs were treated with mitomycin C
or y-irradiated (3000 rads) followed by washing v;~ith AIM-V media.
Cvtotoxic T Ivmphocvte assaus. For the CTL assay, three (HLA.A2+) normal donors' PBLs were used. The T-cells were Grown for five weeks in bulk cultures as described above. At the end of two weeks, live T-cells were harvested from flasks and counted. The targets were mutant T2 cells. Houbiers et al., Eur. J. Immunol 23:2072-2077 (1993); Stauss et al., Proc. Natl. Acad. Sci. U.S.A. 89:7871-787 (1992). The telomerase peptide-mediated upregulation of HLA.A2 expression on T2 cells was examined using the HLA-A2-associated peptides ILAKFLHWL (BPl-187), RLVDDFLLV (BP1-190), and ELLRSFFYV (BP1-191) using known methods. Townsend et al., Nature 346:476 (1989). T2 cells were loaded overnight at 37°C in 7% CO, with various the telomerase synthetic peptides at 200 pM in presence of 8 yg exogenous (32 microglobulin. Houbiers et al., supra; Stauss et al., supra.
The peptide-loaded T2 target cells were loaded with''Cr (using NaCrO~) for 90 minutes and washed. CTL assays were performed as pre~~iously described. Agrawal et al., J.
Immunol.
156:2089 (1996). Percent specific killing was calculated as: experimental release -spontaneous release/maximum release - spontaneous release x 100. The effector versus target ratios used were 50:1, 25:1, 10:1 and S:l . Each group was set up in four replicate and mean percent specific killing was calculated.
Cell Sz~r~'ace Immuno~la~orescence Staining. For detection of cell surface antigens, the peptide-fed T2 cells were washed once in cold PBS containing I%
BSA
followed by addition of 1 pg of anti-A2 monoclonal antibody, .MA2.1 or a control antibody and incubated for 45 minutes on ice. Cells were then washed and a secondary antibody, goat anti-mouse IgG (H+L)-FITC labeled (Southern Biotech) was added for 30 minutes on ice.
B. Results Using the foregoing methods, the cytotoxic activity of T-cells stimulated with autologous APCs pulsed with liposomal telomerase peptide was determined. The source of T-cells was PBLs from three HLA.A2' donors. Target T2 cells (HLA.A2+) were loaded with the telomerase peptide indicated above.
The negative control was T2 cells, and the positive control was the 10-mer flu peptide FLPSDYFPSV, which strongly upreQulates HLA.A2 expression on T2 cells.
These data confirm that the present methods can be used to generate specific, biologically relevant T-cell responses to telomerase, such as cytotoxicity.
Figure 1 shows FACS analysis of cells treated according to the foregoing methods, panel A shows the negative control. Panel B, is the positive control, showing a 227% increase in median channel intensity of A2 expression as compared to the negative control. Panel C, is the experimental with BPl-187, and shows a 396% increase in median channel intensity of A2 expression as compared to the negative control. Panels D and E show the results with BPl-190 and BPl-191, respectively yielding 0% and 6%
increases over the negative control.
Table I shows specific killing of targets by telomerase antigen-primed (BP1-187) cytotoxic T-cells. The negative control was SIINFEKL.
These data indicate that, contrary to expectations, an immune response can be generated against telomerase, a self antigen.
Table I: Telomerase Peptide-Specific Killing TARGET EFFECTOR:T.aRGET RATIO PERCENT KILLING
Unloaded X0:1 35.7 Unloaded 25:1 23.8 Unloaded 10:1 13.1 Unloaded 5:1 5.0 Telomerase Peptide-Loaded50:1 56.7 Telomerase Peptide-Loaded25:1 33.5 Telomerase Peptide-Loaded10:1 21.1 Telomerase Peptide-Loaded5:1 15.5 Control Peptide-Loaded X0:1 32.3 Control Peptide-Loaded 25:1 22.1 Control Peptide-Loaded 10:1 11.3 Control Peptide-Loaded ~:1 7.6 *******
The foregoing detailed description and examples are presented for illustrative purposes only and are not meant to be limiting. Further embodiments of the invention will be ready apparent to the skilled worker in view of this disclosure.
?5
Claims (41)
1. A peptide, comprising less than about 60 amino acids of the native telomerase protein sequence, optionally having one or more conservative substitutions, wherein said peptide is capable of binding at least one human leukocyte antigen (HLA).
2. A peptide according to claim 1. wherein said HLA molecule is a class I
molecule.
molecule.
3. A peptide according to claims 1 or 2 which is about 8 to about 12 amino acids in length.
4. A peptide according to any of claims 1, 2 or 3, comprising the sequence ILAKFLHWL, or a conservative variant thereof.
5. A vaccine, comprising at least a portion of the native telomerase protein sequence, optionally having one or more conservative amino acid substitutions, or a polynucleotide encoding said telomerase portion, and a lipid, wherein said telomerase portion is capable of binding at least one human leukocyte antigen (HLA).
6. A vaccine according to claim 5, wherein said telomerase portion is a peptide of less than about 60 amino acids in length.
7. A vaccine according to claims 5 or 6, wherein said telomerase portion is a peptide of about 8 to about 12 amino acids in length.
8. A vaccine according to any of claims 5, 6 or 7, wherein said lipid is part of a liposome.
9. A method of treating or preventing cancer, comprising administering to a patient in need thereof an effective amount of a composition which comprises at least a portion of the native telomerase protein sequence. optionally having one or more conservative amino acid substitutions, or a polynucleotide encoding said telomerase portion, wherein said portion is capable of binding at least one human leukocyte antigen (HLA).
10. A method according to claim 9, wherein said composition further comprises a lipid.
11. A method according to claims 9 or 10, wherein said telomerase portion is a peptide of less than about 60 amino acids in length.
12. A method according to any of claims 9, 10 or 11, wherein said telomerase portion is a peptide of about 8 to about 12 amino acids in length.
13. A method according to any of claims 10, 11 or 12, wherein said lipid is part of a liposome.
14. A method of treating or preventing cancer, comprising administering to a patient in need thereof a telomerase-primed antigen-presenting cell.
15. A method according to claim 14, wherein said antigen-presenting cell is primed using a composition comprising at least a portion of the native telomerase protein sequence, optionally having one or more conservative amino acid substitutions, or a polynucleotide encoding said telomerase portion, wherein said telomerase portion is capable of binding at least one human leukocyte antigen (HLA).
16. A method according to claim 15, wherein said telomerase portion is a peptide of less than about 60 amino acids in length.
17. A method according to claim 16. wherein said telomerase portion is a peptide of about 8 to about 12 amino acids in length.~
18. A method according to any of claims 15, 16 or 17, wherein the composition further comprises a lipid.~
19. A method according to claim 18, wherein said lipid is in a liposome.
20. A method according to any of claims 14-19, further comprising administering an effective amount of interleukin-2 (IL-2) to said patient.
21. An isolated polynucleotide that encodes a telomerase specific antigen, wherein said polynucleotide is less than about 180 nucleotides in length.
22. A polynucleotide according to claim 21 which is about 24 to about 36 nucleotides in length.
23. A polynucleotide according to claims 21 or 22, wherein said antigen is a class I-specific antigen.
24. A polynucleotide according to any of claims 21, 22 or 23, which encodes a peptide comprising the sequence ILAKFLHWL, or a conservative variant thereof.
25. A method of producing a telomerase-primed antigen-presenting cell, comprising contacting an antigen-presenting cell with a composition comprising at least a portion of the native telomerase protein sequence, optionally having one or more conservative amino acid substitutions, or a polynucleotide encoding said telomerase portion, wherein said telomerase portion is capable of binding at least one human leukocyte antigen (HLA).
26. A method according to claim 25, wherein said telomerase portion is a peptide of less than about 60 amino acids in length.
27. A telomerase-primed antigen-presenting cell which is produced according to claim 25 or 26.
28. A peptide according to claim 2 which is less than about 25 amino acids in length.
29. A polynucleotide according to claim 21 which is less than 75 nucleotides in length.
30. Use of a composition comprising at least a portion of the native telomerase protein sequence, optionally having one or more conservative amino acid substitutions, or a polynucleotide encoding said telomerase portion, wherein said telomerase portion is capable of binding at least one human leukocyte antigen (HLA), for treating or preventing cancer.
31. A use according to claim 30, wherein said composition further comprises a lipid.
32. A use according to claim 31, wherein said lipid is part of a liposome.
33. A use according to any of claims 30-32, wherein said telomerase portion is a peptide of less than about 60 amino acids in length.
34. A use according to any of claims 30-33, wherein said telomerase portion is a peptide of about 8 to about 12 amino acids in length.
35. Use of a telomerase-primed antigen-presenting cell for treating or preventing cancer.
36. A use according to claim 35, wherein the antigen-presenting cell is primed using a composition comprising at least a portion of the native telomerase protein sequence, optionally having one or more conservative amino acid substitutions, or a polynucleotide encoding said telomerase portion, wherein said telomerase portion is capable of binding at least one human leukocyte antigen (HLA).
37. A use according to claim 36, wherein said telomerase portion is a peptide of less than about 60 amino acids in length.
38. A use according to claims 36 or 37, wherein said telomerase portion is a peptide of about 8 to about 12 amino acids in length.
39. A use according to any of claims 36-38, wherein the composition further comprises a lipid.
40. A use according to claim 39, wherein said lipid is in a liposome.
41. Use of a composition comprising a telomerase-primed antigen-presenting cell according to any of claims 15-19, wherein the composition further comprises interleukin-2 (IL-2), for treating or preventing cancer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12853999P | 1999-04-09 | 1999-04-09 | |
US60/128,539 | 1999-04-09 | ||
PCT/IB2000/000610 WO2000061766A2 (en) | 1999-04-09 | 2000-04-07 | Telomerase-specific cancer vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2368967A1 true CA2368967A1 (en) | 2000-10-19 |
Family
ID=22435817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002368967A Abandoned CA2368967A1 (en) | 1999-04-09 | 2000-04-07 | Telomerase-specific cancer vaccine |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1171612A2 (en) |
JP (1) | JP2002541811A (en) |
AU (1) | AU781376B2 (en) |
CA (1) | CA2368967A1 (en) |
WO (1) | WO2000061766A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2321642B8 (en) | 1996-10-01 | 2006-08-22 | Geron Corp | Human telomerase reverse transcriptase promoter |
US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
US7622549B2 (en) | 1997-04-18 | 2009-11-24 | Geron Corporation | Human telomerase reverse transcriptase polypeptides |
US7413864B2 (en) | 1997-04-18 | 2008-08-19 | Geron Corporation | Treating cancer using a telomerase vaccine |
WO1999050392A1 (en) * | 1998-03-31 | 1999-10-07 | Geron Corporation | Methods and compositions for eliciting an immune response to a telomerase antigen |
US7402307B2 (en) | 1998-03-31 | 2008-07-22 | Geron Corporation | Method for identifying and killing cancer cells |
EP1257284A4 (en) * | 2000-02-15 | 2005-12-21 | Univ California | A universal vaccine and method for treating cancer employing telomerase reverse transcriptase |
JP2004527449A (en) | 2000-02-15 | 2004-09-09 | リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Universal vaccine and method for treating cancer using telomerase reverse transcriptase |
GB0031430D0 (en) * | 2000-12-22 | 2001-02-07 | Norsk Hydro As | Polypeptides |
IL159334A0 (en) * | 2001-06-25 | 2004-06-01 | Yissum Res Dev Co | A method for preparation of vesicles loaded with biological material and different uses thereof |
DE102006025146A1 (en) * | 2006-05-30 | 2007-12-06 | Charité - Universitätsmedizin Berlin | Peptide that modulates proteasome activity, e.g. for disease treatment, comprises a human protein sequence |
EP1887084A1 (en) | 2006-08-10 | 2008-02-13 | International Investment and Patents SA | Plasmids with immunological action |
WO2014079464A1 (en) * | 2012-11-21 | 2014-05-30 | Sherif Salah Abdul Aziz | A novel enzymes compositions for treatment of human immunodeficiency virus (hiv) infection |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2321642B8 (en) * | 1996-10-01 | 2006-08-22 | Geron Corp | Human telomerase reverse transcriptase promoter |
DE69842060D1 (en) * | 1997-05-08 | 2011-01-27 | Oncothyreon Inc | Method of obtaining activated T cells and antigen-incubated antigen-presenting cells |
WO1999050392A1 (en) * | 1998-03-31 | 1999-10-07 | Geron Corporation | Methods and compositions for eliciting an immune response to a telomerase antigen |
US7030211B1 (en) * | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
ATE347904T1 (en) * | 1998-10-29 | 2007-01-15 | Dana Farber Cancer Inst Inc | CANCER IMMUNOTHERAPY AND CANCER DIAGNOSIS USING UNIVERSAL TUMOR-ASSOCIATED ANTIGENS INCLUDING HTERT |
-
2000
- 2000-04-07 JP JP2000611689A patent/JP2002541811A/en active Pending
- 2000-04-07 EP EP00920996A patent/EP1171612A2/en not_active Withdrawn
- 2000-04-07 CA CA002368967A patent/CA2368967A1/en not_active Abandoned
- 2000-04-07 WO PCT/IB2000/000610 patent/WO2000061766A2/en not_active Application Discontinuation
- 2000-04-07 AU AU41394/00A patent/AU781376B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU4139400A (en) | 2000-11-14 |
EP1171612A2 (en) | 2002-01-16 |
WO2000061766A3 (en) | 2001-03-08 |
AU781376B2 (en) | 2005-05-19 |
WO2000061766A2 (en) | 2000-10-19 |
JP2002541811A (en) | 2002-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220041655A1 (en) | Class i mhc phosphopeptides for cancer immunotherapy and diagnosis | |
JP6006265B2 (en) | HLA-DR binding peptides and their use | |
EP2089423B1 (en) | Antigen specific multi epitope vaccines | |
ES2537323T3 (en) | CDCA1 peptide and pharmaceutical agent comprising it | |
JP2003521245A (en) | Inducing a Cellular Immune Response to Prostate Cancer Antigen Using Peptide and Nucleic Acid Compositions | |
AU781376B2 (en) | Telomerase-specific cancer vaccine | |
JP2001525668A (en) | Methods for generating activated T cells and antigen-pulsed labeled antigen-presenting cells | |
JP2003530083A (en) | Induction of a Cellular Immune Response to HER2 / neu Using Peptide and Nucleic Acid Compositions | |
JP2003521243A (en) | Heterocritic analogs and related methods | |
JP5799394B2 (en) | NEIL3 peptide and vaccine containing the same | |
Berger et al. | Tumor‐specific peptides in cutaneous T‐cell lymphoma: Association with class I major histocompatibility complex and possible derivation from the clonotypic T‐cell receptor | |
WO2014039675A2 (en) | Target peptides for colorectal cancer therapy and diagnostics | |
JP2003516344A (en) | HLA class IA2 tumor-associated antigenic peptides and vaccine compositions | |
JP2004500059A (en) | Induction of a cellular immune response to carcinoembryonic antigen using peptide and nucleic acid compositions | |
JP6255593B2 (en) | CD1 epitope peptide of Th1 cells and vaccine containing the same | |
JP6999185B2 (en) | CDCA1-derived peptide and vaccine containing it | |
JP6255594B2 (en) | LY6K epitope peptide of Th1 cell and vaccine containing the same | |
RU2531348C2 (en) | Ttk peptides and vaccines containing them | |
MXPA03006581A (en) | Subunit vaccines with a2 supermotifs. | |
CA3124905A1 (en) | Vaccines targeting neoepitopes | |
JP2003517310A (en) | Induction of a cellular immune response against MAGE2 / 3 using peptide and nucleic acid compositions | |
WO2022074098A1 (en) | Method for the identification of cancer neoantigens | |
JP2003516131A (en) | Induction of a cellular immune response against P53 using peptide and nucleic acid compositions | |
RU2700881C2 (en) | Urlc10-derived peptide and vaccine containing same | |
JP2018508181A (en) | GPC3 epitope peptide for Th1 cells and vaccine containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDC | Discontinued application reinstated | ||
EEER | Examination request | ||
FZDE | Discontinued |